Sherif S Farag

Summary

Affiliation: The Ohio State University
Country: USA

Publications

  1. ncbi request reprint Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    Blood 100:1935-47. 2002
  2. ncbi request reprint Immunologic approaches to acute leukemia in the elderly
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Semin Hematol 43:118-25. 2006
  3. ncbi request reprint The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry
    Sherif S Farag
    The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:876-84. 2006
  4. pmc Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:63-73. 2006
  5. ncbi request reprint Human natural killer cell development and biology
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, A312 Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
    Blood Rev 20:123-37. 2006
  6. ncbi request reprint Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    J Clin Oncol 23:482-93. 2005
  7. pmc A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation
    Xiaodong Tong
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus Ohio, USA
    Exp Hematol 35:1613-22. 2007
  8. doi request reprint Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
  9. pmc A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 120:4324-33. 2012
  10. pmc IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH, USA
    Blood 118:6387-91. 2011

Research Grants

Detail Information

Publications32

  1. ncbi request reprint Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology Oncology, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    Blood 100:1935-47. 2002
    ..Here, we review how NK cell receptors control natural cytotoxicity and novel approaches to manipulating NK receptor-ligand interactions for the potential benefit of patients with cancer...
  2. ncbi request reprint Immunologic approaches to acute leukemia in the elderly
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    Semin Hematol 43:118-25. 2006
    ..In this review, we discuss the biologic rationale for therapeutic strategies harnessing NK cells and focus on novel directions for their future use in elderly patients with acute leukemia...
  3. ncbi request reprint The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry
    Sherif S Farag
    The Ohio State University, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:876-84. 2006
    ..There were no differences in leukemia recurrence between the 4 groups. These results do not support the choice of an unrelated donor on the basis of KIR ligand mismatch determined from HLA typing...
  4. pmc Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Blood 108:63-73. 2006
    ..Patients with complex > or = 5 appear to benefit minimally from current treatment and are better suited for investigational therapy or supportive care...
  5. ncbi request reprint Human natural killer cell development and biology
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, A312 Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
    Blood Rev 20:123-37. 2006
    ..In this review, we summarize current understanding of NK cell biology, and highlight how such knowledge may be translated to optimize the efficacy of using autologous or allogeneic NK cell for the immunotherapy of cancer...
  6. ncbi request reprint Outcome of induction and postremission therapy in younger adults with acute myeloid leukemia with normal karyotype: a cancer and leukemia group B study
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 W Tenth Avenue, Columbus, OH 43210, USA
    J Clin Oncol 23:482-93. 2005
    ..Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML)...
  7. pmc A novel high throughput immunomagnetic cell sorting system for potential clinical scale depletion of T cells for allogeneic stem cell transplantation
    Xiaodong Tong
    Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus Ohio, USA
    Exp Hematol 35:1613-22. 2007
    ..0 log(10)), high level of recovery of hematopoietic stem cells (>90%), with a high throughput (>10(6) cells/second)...
  8. doi request reprint Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation
    Mehdi Hamadani
    Division of Hematology and Oncology, Arthur G James Cancer Hospital, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Biol Blood Marrow Transplant 14:783-9. 2008
    ..The addition of infliximab to standard GVHD prophylaxis did not lower the risk of GVHD and was associated with an increased risk of bacterial and invasive fungal infections...
  9. pmc A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH 43210 1240, USA
    Blood 120:4324-33. 2012
    ..These findings suggest that IPH2101 is safe and tolerable at doses that achieve full inhibitory KIR saturation, and this approach warrants further development in MM. This trial was registered at www.clinicaltrials.gov as #NCT00552396...
  10. pmc IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect
    Don M Benson
    Division of Hematology, The Ohio State University, Columbus, OH, USA
    Blood 118:6387-91. 2011
    ..These mechanistic, preclinical data support the use of a combination of IPH2101 and lenalidomide in a phase 2 trial for MM...
  11. ncbi request reprint FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia
    Thomas S Lin
    Department of Medicine, Division of Hematology Oncology, The Ohio State University, Columbus 43210, USA
    Blood 105:289-91. 2005
    ..Future studies examining larger cohorts of alemtuzumab-treated patients with CLL will be required to definitively determine the predictive value of specific FCGR polymorphisms to treatment response...
  12. ncbi request reprint Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210, USA
    Clin Cancer Res 8:2812-9. 2002
    ..The purpose of the study is to investigate the tolerability of interleukin 2 (IL-2) after intensive chemotherapy in elderly acute myeloid leukemia (AML) patients in first complete remission (CR)...
  13. ncbi request reprint Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Sherif S Farag
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University, A433A Starling Loving Hall, 320 West Tenth Avenue, Columbus, OH 43210, USA
    Int J Oncol 21:1041-51. 2002
    ..We conclude that in de novo adult AML patients not receiving SCT, IT(C) appears to independently predict a poor outcome that may be improved with SCT in first remission. Prospective studies are required to confirm this hypothesis...
  14. ncbi request reprint High disease burden is associated with poor outcomes for patients with acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation
    William Blum
    Division of Hematology and Oncology and Comprehensive Cancer Center, The Ohio State University Hospitals, Columbus, Ohio 43210, USA
    Biol Blood Marrow Transplant 12:61-7. 2006
    ....
  15. doi request reprint The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
    Shuhong Zhang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
    Int J Cancer 129:204-13. 2011
    ..In conclusion, AR-42 has potent cytotoxicity against MM cells mainly through gp130/STAT-3 pathway. The results provide rationale for clinical investigation of AR-42 in MM...
  16. ncbi request reprint High-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma
    Don M Benson
    Division of Hematology and Oncology, Department of Internal Medicine, The Ohio State University College of Medicine, Comprehensive Cancer Center, Starling Loving Hall, Columbus, OH 43210, USA
    Leuk Res 31:1069-75. 2007
    ..BCV and HDM confer similar long-term outcomes with similar toxicity profiles as conditioning regimens prior to autologous stem cell transplant in patients with MM...
  17. doi request reprint From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma
    Shuhong Zhang
    Indiana University School of Medicine, Division of Hematology and Oncology, Department of Medicine, Indianapolis, IN 46202, USA
    Expert Opin Investig Drugs 20:1015-28. 2011
    ..ENMD-2076 is an orally bioavailable, multi-target kinase inhibitor with multiple mechanisms of action, including anti-proliferative and pro-apoptotic activity, and anti-angiogenic effects...
  18. doi request reprint Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma
    Xiaojing Wang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA
    Br J Haematol 150:313-25. 2010
    ..These results provide preclinical rationale for clinical investigation of ENMD-2076 in MM...
  19. ncbi request reprint New directions in natural killer cell-based immunotherapy of human cancer
    Sherif S Farag
    Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA
    Expert Opin Biol Ther 3:237-50. 2003
    ..In this review, the impact of NKR biology on the development of novel strategies for the use of NK cells in the treatment of human cancer is discussed...
  20. ncbi request reprint Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B study
    Sherif S Farag
    The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
    Int J Oncol 25:143-51. 2004
    ..We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy...
  21. ncbi request reprint Biology and clinical impact of human natural killer cells
    Sherif S Farag
    Department of Internal Medicine, Division of Hematology and Oncology, The Ohio State University, Columbus, Ohio 43210, USA
    Int J Hematol 78:7-17. 2003
    ..We review recent development in the biology and clinical relevance of NK cells in cancer immunotherapy...
  22. ncbi request reprint Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma
    Sherif S Farag
    Division of Hematology and Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio 43210, USA
    Adv Pharmacol 51:295-318. 2004
  23. pmc Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein
    Craig C Hofmeister
    The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 29:3427-34. 2011
    ..The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM...
  24. ncbi request reprint OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms
    Shuhong Zhang
    Division of Hematology and Oncology, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 13:4750-8. 2007
    ..We investigated the in vitro activity of OSU-03012 in multiple myeloma (MM) cells...
  25. ncbi request reprint Monoclonal antibodies for the prevention and treatment of graft-versus-host disease
    Rebecca J Bruner
    Bone Marrow Transplantation Program, The Ohio State University Comprehensive Cancer Center, Columbus, USA
    Semin Oncol 30:509-19. 2003
    ..Over the next decade, however, the challenge will be to define the relative place of these antibodies in the therapeutic armamentarium for GvHD and their impact on long-term survival...
  26. ncbi request reprint Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
    Sherif S Farag
    Division of Hematology Oncology and the Department of Biostatistics, The Ohio State University, Columbus, OH 43210, USA
    Blood 103:1472-4. 2004
    ..These data suggest that Fc gamma RIIIa polymorphisms are not predictive of response in CLL and that, unlike the case with FL, mechanisms of tumor clearance other than antibody-dependent cellular cytotoxicity may be more important...
  27. pmc Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease
    Ming J Poi
    Department of Pharmacy, The Arthur G James Cancer Hospital and Richard J Solove Research Institute, The Ohio State University, Columbus, OH, USA
    Clin Pharmacokinet 52:705-12. 2013
    ..This phase II study (NCT00201786) was conducted to assess pentostatin efficacy and infectious complications seen from our previous phase I study in steroid-refractory acute GVHD (aGVHD)...
  28. pmc The potential role of Aurora kinase inhibitors in haematological malignancies
    Sherif S Farag
    Division of Hematology and Oncology, Department of Medicine, Indiana University School of Medicine, 840 Westr Walnut St, Indianapolis, IN 46202, USA
    Br J Haematol 155:561-79. 2011
    ....
  29. ncbi request reprint Comparison of two immunomagnetic separation technologies to deplete T cells from human blood samples
    Oscar Lara
    Department of Chemical and Biomolecular Engineering, The Ohio State University, 120 Koffolt Laboratories, 140 W 19th Avenue, Columbus, 43210, USA
    Biotechnol Bioeng 94:66-80. 2006
    ....
  30. pmc Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT
    Jeffery S Miller
    Divisions of Adult and Pediatric Hematology, Oncology and Transplantation, University of Minnesota Cancer Center, Harvard Street at East River Road, Minneapolis, MN 55455, USA
    Blood 109:5058-61. 2007
    ..58, 95% CI 1.13-2.22; P = .008). These data support a genetically determined role for NK cells following unrelated HCT in myeloid leukemia...
  31. ncbi request reprint Immunotherapeutic strategies of stem cell transplant in lymphoma
    Sherif S Farag
    Division of Hematology Oncology, Ohio State University Comprehensive Cancer Center, USA
    Clin Adv Hematol Oncol 2:638-40. 2004
  32. doi request reprint Antimyeloma effects of a sesquiterpene lactone parthenolide
    Attaya Suvannasankha
    Hematology and Oncology Division, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 14:1814-22. 2008
    ..The sesquiterpene lactone parthenolide targets NF-kappaB. However, its therapeutic potential in MM is not known...

Research Grants6

  1. Innate Immune Cell Therapy with Stem Cell Transplants
    Sherif Farag; Fiscal Year: 2003
    ..The clinical and laboratory data derived from this trial will form the basis for future phase II studies to investigate the efficacy of this immunotherapy approach. ..
  2. NK Cell Recognition of Leukemia Blasts and IL-2 Therapy
    Sherif Farag; Fiscal Year: 2004
    ..The results of our studies may provide a means of identifying which subset of AML cases are susceptible to IL-2 therapy, and therefore, may ultimately assist in the better selection of patients for NK cell-based therapies. ..
  3. mTOR Inhibition as a Therapeutic Target in Myeloma
    Sherif Farag; Fiscal Year: 2005
    ..The results of this research have important significance for the treatment of MM and may lead to a novel therapeutic approach in this disease. ..
  4. QMS Technology to Deplete T Cell Alloreactivity
    Sherif Farag; Fiscal Year: 2007
    ..abstract_text> ..